Notice convening the Annual General Meeting of Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Notice convening the Annual General Meeting of Shareholders in Oasmia Pharmaceutical AB

Uppsala, Sweden, 2016-08-26 08:30 CEST (GLOBE NEWSWIRE) --  

Registration and notification

Shareholders who wish to participate in the Annual General Meeting must be recorded in the share register kept by Euroclear Sweden AB on Tuesday, September 20, 2016, and give notice of intent to participate to the Company not later than 4 p.m. on Thursday, September 22, 2016 by either letter to Oasmia Pharmaceutical AB, Vallongatan 1, SE-752 28 Uppsala, Sweden, by fax: +46 18 51 08 73 or by e-mail: info@oasmia.com , including the number of assistants. Shareholders that have their shares registered in the name of a nominee must, in addition to giving notice of participation in the Meeting, temporarily be recorded in the share register in their own names (so called voting-rights registration) to be able to participate in the General Meeting. Such registration must be effectuated on, September 20, 2016, at the latest. Shareholders represented by an agent shall to the agent issue a written, dated proxy and shall submit the proxy to the Company prior to the Annual General Meeting. The proxy and any other authorization documents, such as registrations, shall be available at the Meeting. Such authorization documents should also be attached to the notice. For those who wish to be represented by agents, the Company will provide proxies which will be available on the Company website, http://www.oasmia.com .  

Agenda  

1.    Opening of the Meeting

2.    Election of Chairman of the Meeting

3.    Preparation and approval of the voting list

4.    Approval of the agenda

5.    Election of one or two verifiers

6.    Determination as to whether the Meeting has been properly convened.

7.    Presentation by the Chief Executive Officer

8.    Presentation of the Annual Report and the Consolidated Accounts as well as the Audit Report and the Audit Report for the Group

9.    Resolution on

a)     adoption of the Income Statement and the Balance Sheet as well as the Consolidated Income Statement and the Consolidated Balance Sheet

b)     dispositions in respect of the Company’s profit or loss pursuant to the adopted Balance Sheet

c)      discharge from liability of the Directors and the Chief Executive Officer

10. Determination of the number of Directors

11. Determination of fee to the Board of Directors and the Auditors

12. Election of Board of Directors, Chairman of the Board of Directors and auditors

13. Decision on the nomination committee prior to the 2017 Annual General Meeting

14. Decision on remuneration guidelines for senior executive management

15. Decision on authorization of repurchase and transfer the company´s own shares

16. Decision on authorization for the Board to propose new issue of share, warrants and convertibles

17. Closing of the Meeting.

 

PROPOSALS FOR DECISION  

The nomination committee has had one meeting during the year and proposes as follows  

Item 2 Proposal of Erik Nerep as Chairman of the Meeting. Item 10 Six members without deputies. Item 11 Board members who are not employed by the Company shall receive remuneration of SEK 150 000 per year. The Chairman of the Board shall receive remuneration of SEK 175 000. The Board remuneration may, following a specific agreement with Oasmia Pharmaceutical AB, be invoiced by a company that is wholly-owned by the board member. If this occurs, the invoiced remuneration shall be increased by an amount corresponding to social charges and VAT. Julian Aleksov has informed that he renounce his remuneration until the next annual general meeting. The auditors shall be remunerated according to invoice. Item 12 Re-election of Julian Aleksov, Horst Domdey, Bo Cederstrand Alexander Kotsinas, Lars Bergkvist and Hans Sundin. Julian Aleksov is proposed as Executive Chairman of the Board of Directors. Ernst & Young AB is proposed as auditing company, with Fredrik Norman as principal auditor. Item 13 The nomination committee proposes the following criteria for the nomination committee process prior to the 2017 Annual General Meeting. The nomination committee shall consist of the chairman of the board and two other members appointed by the two largest shareholders in terms of voting rights in Oasmia Pharmaceutical as of September 30, 2016. The committee shall elect its chairman among its members. The chairman of the board may not serve as a chairman of the nomination committee.  

The Board of Directors proposes as follows

Proposal for resolution on the dispositions in respect of the Company’s profit/loss pursuant to the adopted Balance Sheet (item 9b)

The Board proposes that no dividends shall be paid and that share premium reserve SEK 941 960 675, accumulated losses SEK -489 921 393 and income for the year SEK ‑141 673 259, in total SEK 310 366 023 will be carried forward.  

Proposal for resolution on remuneration guidelines for senior executives (Item 14).

The Board of Directors proposes the following guidelines for remuneration to senior executives that are intended to apply as of the 2016 Annual General Meeting until the 2017 Annual General Meeting. By senior executives is meant the CEO and other members of the management team at Oasmia, as well as members of the Board to the extent they receive remuneration for other work than their Board assignment.  

Pay and other benefits

Remuneration to senior executives shall consist of fixed salary, pension allocations and health insurance.  

Period of notice and severance pay

In the event of termination on the part of the Company, the period of notice for the CEO shall be no more than 12 months. In the event of termination on the part of the CEO, the period of notice shall be no more than three months. For other people in the Company management, the period of notice shall normally be six months if termination is initiated by the Company, and three months if termination is initiated by the employee. No special severance pay shall be paid.  

Incentive program

A decision regarding any shares and share price-related incentive programs aimed at people in the Company management shall be made by the General Meeting.  

Policy

The more detailed principles for salary payment to the CEO and other members of the Company management shall be documented in a policy established by the Board.  

Deviation in individual cases

The Board shall be entitled to deviate from said guidelines if there are special grounds in an individual case. If such a deviation is made, information on this and the reason for the deviation shall be reported at the next Annual General Meeting.  

Proposal for the authorization of repurchase and transfer the Company´s own shares (Item 15)

The Board of Directors proposes that the Meeting authorizes the Board of Directors to resolve to repurchase, on one or several occasions prior to the next annual general meeting, as many shares as may be purchased without the Company’s holding at any time exceeds 10 per cent of the total number of shares in the Company. The shares shall be purchased on NASDAQ Stockholm and only at a price within the price range registered at any given time, i.e. the range between the highest bid price and the lowest offer price.                                                                                                        

The Board of Directors also proposes that the Board of Directors shall be authorized to resolve, on one or several occasions during the period until the next annual general meeting, to transfer all shares held by the Company, via NASDAQ Stockholm or in connection with the acquisition of companies, businesses or parts thereof on market terms, however, not to a price lower than current stock market value. Transfer of shares on the NASDAQ Stockholm may at a price within the price range registered at any given time, i.e. the range between the highest bid price and the lowest offer price.  

The purpose of the proposed authorizations is to provide flexibility as regards the Company’s possibilities to distribute capital to its shareholders and to promote more efficient capital usage in the Company.  

Authorization for the Board to propose new issue of share, warrants and convertibles (Item 16)

The Board of Directors proposes that the General Meeting of Shareholders resolves to authorize the Board of Directors to, on one or several occasions during the period up to the next annual General Meeting of Shareholders, resolve on an issue of shares, warrants and/or convertible instruments. The Board of Directors shall be authorized to adopt decisions on an issue of shares, warrants and/or convertible instruments with deviation from the shareholders’ pre-emption rights and/or an issue in kind or an issue by way of set-off or otherwise on such terms and conditions as referred to in Chapter 2, Section 5, second paragraph, points 1-3 and 5, of the Swedish Companies Act. The new shares, warrants and/or convertible instruments shall, in the event of a deviation from the shareholders’ pre-emption rights, be issued at a subscription price which connects to the stock price at the time of the issue, decreased by a market rate discount that the Board of Directors deems necessary (if any).  

The reason that the Board of Directors shall be authorized to resolve on an issue with deviation from the shareholders’ pre-emption rights and/or an issue in kind or an issue by way of set-off or otherwise on such terms and conditions as referred to above is that the Company shall be able to issue shares, warrants and/or convertible instruments in connection with acquisitions of companies or businesses and to carry-out directed issues in order to raise capital or broaden the ownership of the Company. The Board of Directors shall however not be entitled to make resolutions which entail that the share capital is increased with more than SEK 3 500 000.  

It is also proposed that the Board of Directors, or any person appointed by the Board, is authorized to make such minor adjustments to this resolution that may be necessary in connection with the registration with the Swedish Companies Registration Office and/or Euroclear Sweden AB.  

Majority requirements

The Meeting’s resolution regarding item 15 must, in order to be valid, be supported by shareholders representing at least two thirds of the votes cast as well as of the shares represented at the Meeting. Resolution regarding item 16 requires the resolution to be supported by shareholders representing at least 9/10 of the votes cast as well as of the shares represented at the meeting.  

Right to information

The Board of Directors and the Chief Executive Officer must, if a shareholder requests it and the Board considers that it can be made without considerable damage to the Company, provide information at the Annual General Meeting about conditions which may affect the estimation of the Company or of the subsidiaries financial situation to another group company.  

Documents

The Annual Report and Audit report, proxies and full proposals as stated above that will be put forward to the Meeting will be available on the Company website http://www.oasmia.com and at Oasmia Pharmaceutical AB, Vallongatan 1, Uppsala, Sweden, phone +46 18 50 54 40, not later than three weeks prior to the Annual General Meeting and will be sent to shareholders upon request.  

Shares and votes

The Company’s shares are issued in one series. All shares carrying equal voting rights at the General Meeting. There are in total 107,209,310 shares in the Company, accordingly there are in total 107,209,310 votes.

 

Uppsala August 26, 2016

The Board of Directors for Oasmia Pharmaceutical AB (publ.)  

Notes to editors:  

About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

         Anders Blom          Tel: +46 18 50 54 40          E-mail: anders.blom@oasmia.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 95

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 86

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 102

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 121

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look

Updated Category News Views 75

A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 111

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 72

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 139

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 119

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading

Top 5 Most Recently Viewed Articles

Ollie's Bargain Outlet Raises Over $1.3 Million for Charity

Updated Category News Views 216

Ollie's Bargain Outlet Makes a Difference this Holiday Season Ollie's Bargain Outlet recently announced an impressive fundraising effort, raising over $1.3 million for the Marine Toys for Tots Program. This initiative highlights the company's commitment to giving back to the community during the holiday season. From early November to early December, participating Ollie's...

Continue Reading
Navigating the Integer Holdings Corporation Class Action Concerns

Updated Category News Views 147

Your Rights as an Investor in Integer Holdings Corporation If you've invested in Integer Holdings Corporation (NYSE: ITGR), you might be feeling concerned about recent developments. The company, known for its role in cardiac rhythm management and cardiovascular product manufacturing, is currently under scrutiny due to allegations that it misled investors regarding the...

Continue Reading
Indochino Welcomes Sean Wrenn as New Vice President of Retail

Updated Category News Views 163

Indochino Welcomes Sean Wrenn as New Vice President of Retail INDOCHINO, the leader in made to measure apparel, has appointed Sean Wrenn as the new Vice President of Retail Sales and Operations. With over two decades of retail experience, Sean is set to enhance the company’s operations and customer engagement. Sean Wrenn's Background and Expertise Sean Wrenn joins...

Continue Reading
Innovative Partnership Enhances Efficiency in Dairy Processing

Updated Category News Views 200

Collaboration to Boost Dairy Processing Efficiency In an exciting development within the dairy processing sector, CADDi, a renowned provider of digital solutions for manufacturers, has teamed up with Dairy Conveyor Corporation (DCC Automation). This collaboration marks a significant step towards optimizing supply chains and fostering better communication across DCC's...

Continue Reading
Celebrating Food and Beverage Excellence in the Middle East

Updated Category News Views 171

Celebrating Excellence in Food and Beverage The Middle East Food & Beverage Excellence Awards is an annual event that brings together the best in the industry, turning the spotlight on the remarkable achievements of food and beverage professionals. Last night, at the stunning JW Marriott Marina, industry leaders in the Middle East gathered for an unforgettable evening...

Continue Reading